Updates on Pharmacological Treatment of Post-Traumatic Stress Disorder

  • Rishav Koirala Institute of Clinical Medicine, Faculty of Medicine,University of Oslo ; Psycho-oncology Clinic, Nepal Cancer Hospital and Research Center, Harisiddhi, Lalitpur, Nepal
  • Erik Ganesh Iyer Søegaard Institute of Clinical Medicine, Faculty of Medicine, University of Oslo; Division of Mental Health and Addiction, Oslo University Hospital
  • Suraj Bahadur Thapa Institute of Clinical Medicine, Faculty of Medicine, University of Oslo; Division of Mental, Health and Addiction, Oslo University Hospital, Oslo


Post-Traumatic Stress Disorder affects a significant proportion of those who have been exposed to exceptionally threatening or catastrophic events or situations such as earthquakes, rape and civil war. The condition can often become chronic and disabling. Medical intervention can therefore be of paramount importance. There are no national guidelines for trauma disorders in Nepal and there is a lack of adequate knowledge regarding drug treatment of PTSD among doctors and other service providers. Though psychotherapy is internationally regarded as the first line treatment for PTSD, it is often not feasible in Nepal due to lack of resources and skilled health workers in this field. The use of right psycho-pharmacotherapy is therefore important to reduce the burden of disease. A wide range of pharmacotherapy has been tested in the treatment of PTSD. This article is based on a selected sample of relevant articles from PubMed, PsycINFO, national guidelines from other countries and our own clinical experience. We have tried to give a concise and practical review regarding the use of drugs, their side effects and available evidence in the treatment of PTSD. The main findings point to use of Selective Serotonin Reuptake Inhibitors as the first line pharmacotherapy, and they can have effect on the full range of symptoms in PTSD. SNRIs show similar efficacy. Adjuvant drugs like Alpha-blockers and atypical antipsychotics have shown strong evidence in treating partially remitted cases and resolving ancillary symptoms.

Keywords: Antidepressive Agents; Drug Therapy; Post-Traumatic; Psychotropic Drugs; Stress Disorder[PubMed]


1. World Health Organization. The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992. xii, 362 p. p.
2. Thapa SB, Hauff E. Psychological distress among displaced persons during an armed conflict in Nepal. Soc Psychiatry Psychiatr Epidemiol. 2005;40(8):672-9;10.1007/s00127-005-0943-9; http://www.ncbi.nlm.nih.gov/pubmed/16021344
3. Ursano RJ, Bell C, Eth S, Friedman M, Norwood A, Pfefferbaum B, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry. 2004;161(11 Suppl):3-31 https://www.ncbi.nlm.nih.gov/pubmed/15617511
4. Post-traumatic stress disorder: management [Internet]. NICE. 2014. Available from: https://www.nice.org.uk/guidance/cg26.
5. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84;10.3109/13651501.2012.667114; https://www.ncbi.nlm.nih.gov/pubmed/22540422
6. World Health Organization. The ICD-10 classification of mental and behavioural disorders : diagnostic criteria for research. Geneva: World Health Organization; 1993. xiii, 248 p. p.
7. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013. xliv, 947 p. p.
8. Brownlow JA, Harb GC, Ross RJ. Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature. Curr Psychiatry Rep. 2015;17(6):41;10.1007/s11920-015-0587-8; https://www.ncbi.nlm.nih.gov/pubmed/25894359
9. Spoormaker VI, Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? Sleep Med Rev. 2008;12(3):169-84;10.1016/j.smrv.2007.08.008; https://www.ncbi.nlm.nih.gov/pubmed/18424196
10. Germain A. Sleep disturbances as the hallmark of PTSD: where are we now? Am J Psychiatry. 2013;170(4):372-82;10.1176/appi.ajp.2012.12040432; PMC4197954 https://www.ncbi.nlm.nih.gov/pubmed/23223954
11. Yehuda R, Flory JD, Southwick S, Charney DS. Developing an agenda for translational studies of resilience and vulnerability following trauma exposure. Ann N Y Acad Sci. 2006;1071:379-96;10.1196/annals.1364.028; http://www.ncbi.nlm.nih.gov/pubmed/16891584
12. Olff M, Guzelcan Y, de Vries GJ, Assies J, Gersons BP. HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneuroendocrinology. 2006;31(10):1220-30;10.1016/j.psyneuen.2006.09.003; https://www.ncbi.nlm.nih.gov/pubmed/17081699
13. Passos IC, Vasconcelos-Moreno MP, Costa LG, Kunz M, Brietzke E, Quevedo J, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2(11):1002-12;10.1016/S2215-0366(15)00309-0; https://www.ncbi.nlm.nih.gov/pubmed/26544749
14. Kilpatrick DG, Koenen KC, Ruggiero KJ, Acierno R, Galea S, Resnick HS, et al. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am J Psychiatry. 2007;164(11):1693-9;10.1176/appi.ajp.2007.06122007; https://www.ncbi.nlm.nih.gov/pubmed/17974934
15. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048-60 http://www.ncbi.nlm.nih.gov/pubmed/7492257
16. Pratchett LC, Daly K, Bierer LM, Yehuda R. New approaches to combining pharmacotherapy and psychotherapy for posttraumatic stress disorder. Expert Opin Pharmacother. 2011;12(15):2339-54;10.1517/14656566.2011.604030; https://www.ncbi.nlm.nih.gov/pubmed/21819273
17. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006(1):CD002795;10.1002/14651858.CD002795.pub2; http://www.ncbi.nlm.nih.gov/pubmed/16437445
18. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015;206(2):93-100;10.1192/bjp.bp.114.148551; http://www.ncbi.nlm.nih.gov/pubmed/25644881
19. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012;15(6):825-40;10.1017/S1461145711001209; http://www.ncbi.nlm.nih.gov/pubmed/21798109
20. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013;74(6):e541-50;10.4088/JCP.12r08225; http://www.ncbi.nlm.nih.gov/pubmed/23842024
21. Stahl SM. Stahl's essential psychopharmacology : prescriber's guide. Fifth edition. ed. New York, NY: Cambridge University Press; 2014. xvi, 802 pages p.
22. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006;26(3):259-67;10.1097/01.jcp.0000222514.71390.c1; https://www.ncbi.nlm.nih.gov/pubmed/16702890
23. Lipinska G, Baldwin DS, Thomas KG. Pharmacology for sleep disturbance in PTSD. Hum Psychopharmacol. 2016;31(2):156-63;10.1002/hup.2522; https://www.ncbi.nlm.nih.gov/pubmed/26856810
24. Puetz TW, Youngstedt SD, Herring MP. Effects of Pharmacotherapy on Combat-Related PTSD, Anxiety, and Depression: A Systematic Review and Meta-Regression Analysis. PLoS One. 2015;10(5):e0126529;10.1371/journal.pone.0126529; PMC4447407 http://www.ncbi.nlm.nih.gov/pubmed/26020791
25. Davidson J. Vintage treatments for PTSD: a reconsideration of tricyclic drugs. J Psychopharmacol. 2015;29(3):264-9;10.1177/0269881114565143; http://www.ncbi.nlm.nih.gov/pubmed/25586404
26. Singh B, Hughes AJ, Mehta G, Erwin PJ, Parsaik AK. Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. Prim Care Companion CNS Disord. 2016;18(4);10.4088/PCC.16r01943; https://www.ncbi.nlm.nih.gov/pubmed/27828694
27. Khachatryan D, Groll D, Booij L, Sepehry AA, Schutz CG. Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials. Gen Hosp Psychiatry. 2016;39:46-52;10.1016/j.genhosppsych.2015.10.007; https://www.ncbi.nlm.nih.gov/pubmed/26644317
28. Giustino TF, Fitzgerald PJ, Maren S. Revisiting propranolol and PTSD: Memory erasure or extinction enhancement? Neurobiol Learn Mem. 2016;130:26-33;10.1016/j.nlm.2016.01.009; PMC4818733 https://www.ncbi.nlm.nih.gov/pubmed/26808441
29. Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol. 2016;30(2):128-39;10.1177/0269881115612236; PMC4724794 https://www.ncbi.nlm.nih.gov/pubmed/26487439
30. Alao A, Selvarajah J, Razi S. The use of clonidine in the treatment of nightmares among patients with co-morbid PTSD and traumatic brain injury. Int J Psychiatry Med. 2012;44(2):165-9;10.2190/PM.44.2.g; https://www.ncbi.nlm.nih.gov/pubmed/23413663
31. Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev. 2012;49(5):703-15 https://www.ncbi.nlm.nih.gov/pubmed/23015581
32. Alderman CP, McCarthy LC, Marwood AC. Pharmacotherapy for post-traumatic stress disorder. Expert Rev Clin Pharmacol. 2009;2(1):77-86;10.1586/17512433.2.1.77; https://www.ncbi.nlm.nih.gov/pubmed/24422773
33. Han C, Pae CU, Wang SM, Lee SJ, Patkar AA, Masand PS, et al. The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. J Psychiatr Res. 2014;56:72-81;10.1016/j.jpsychires.2014.05.003; https://www.ncbi.nlm.nih.gov/pubmed/24882700
34. Liu XH, Xie XH, Wang KY, Cui H. Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Psychiatry Res. 2014;219(3):543-9;10.1016/j.psychres.2014.05.027; http://www.ncbi.nlm.nih.gov/pubmed/25015709
35. Carey P, Suliman S, Ganesan K, Seedat S, Stein DJ. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol. 2012;27(4):386-91;10.1002/hup.2238; http://www.ncbi.nlm.nih.gov/pubmed/22730105
36. Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006;21(5):275-80 https://www.ncbi.nlm.nih.gov/pubmed/16877898
37. Villarreal G, Hamner MB, Canive JM, Robert S, Calais LA, Durklaski V, et al. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2016;173(12):1205-12;10.1176/appi.ajp.2016.15070967; https://www.ncbi.nlm.nih.gov/pubmed/27418378
38. Murray B Stein M, MPH. Pharmacotherapy for posttraumatic stress disorder in adults. In: Richard Hermann M, editor. UpToDate. Waltham, MA. (Accessed on March 26, 2013.): UpToDate; 2017.
39. Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry. 2001;62 Suppl 17:60-3 https://www.ncbi.nlm.nih.gov/pubmed/11495099
40. Kishimoto A, Goto Y, Hashimoto K. Post-traumatic Stress Disorder Symptoms in a Female Patient Following Repeated Teasing: Treatment with Gabapentin and Lamotrigine and the Possible Role of Sensitization. Clin Psychopharmacol Neurosci. 2014;12(3):240-2;10.9758/cpn.2014.12.3.240; PMC4293172 https://www.ncbi.nlm.nih.gov/pubmed/25598830
41. Adamou M, Puchalska S, Plummer W, Hale AS. Valproate in the treatment of PTSD: systematic review and meta analysis. Curr Med Res Opin. 2007;23(6):1285-91;10.1185/030079907X188116; https://www.ncbi.nlm.nih.gov/pubmed/17559727
42. Martin C. Comprehensive guide to post-traumatic stress disorders. New York, NY: Springer Berlin Heidelberg; 2016. pages cm p.
43. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry. 2008;69(6):959-65 http://www.ncbi.nlm.nih.gov/pubmed/18588361
44. Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv. 2008;59(10):1184-90;10.1176/appi.ps.59.10.1184; http://www.ncbi.nlm.nih.gov/pubmed/18832505
45. Myers KM, Carlezon WA, Jr., Davis M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology. 2011;36(1):274-93;10.1038/npp.2010.88; PMC2994960 https://www.ncbi.nlm.nih.gov/pubmed/20631689
46. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-26;10.1016/j.biopsych.2008.01.012; https://www.ncbi.nlm.nih.gov/pubmed/18313643
47. Koch SB, van Zuiden M, Nawijn L, Frijling JL, Veltman DJ, Olff M. Intranasal Oxytocin Normalizes Amygdala Functional Connectivity in Posttraumatic Stress Disorder. Neuropsychopharmacology. 2016;41(8):2041-51;10.1038/npp.2016.1; PMC4908648 https://www.ncbi.nlm.nih.gov/pubmed/26741286
48. Palgi S, Klein E, Shamay-Tsoory SG. Oxytocin improves compassion toward women among patients with PTSD. Psychoneuroendocrinology. 2016;64:143-9;10.1016/j.psyneuen.2015.11.008; https://www.ncbi.nlm.nih.gov/pubmed/26671007
49. Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2014;7:CD006239;10.1002/14651858.CD006239.pub2; http://www.ncbi.nlm.nih.gov/pubmed/25001071
50. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-8;10.1001/jamapsychiatry.2014.62; http://www.ncbi.nlm.nih.gov/pubmed/24740528
51. Waller RJ. Fostering child & adolescent mental health in the classroom. Thousand Oaks: Sage Publications; 2006. xi, 339 p. p.
52. Ragen BJ, Seidel J, Chollak C, Pietrzak RH, Neumeister A. Investigational drugs under development for the treatment of PTSD. Expert Opin Investig Drugs. 2015;24(5):659-72;10.1517/13543784.2015.1020109; https://www.ncbi.nlm.nih.gov/pubmed/25773140
53. Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38(12):2952-61;10.1016/j.psyneuen.2013.08.004; PMC3870889 https://www.ncbi.nlm.nih.gov/pubmed/24035186
54. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18(9):1034-40;10.1038/mp.2013.61; PMC3752332 https://www.ncbi.nlm.nih.gov/pubmed/23670490
55. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84-8;10.1111/j.1755-5949.2008.00071.x; https://www.ncbi.nlm.nih.gov/pubmed/19228182
How to Cite
KOIRALA, Rishav; SØEGAARD, Erik Ganesh Iyer; THAPA, Suraj Bahadur. Updates on Pharmacological Treatment of Post-Traumatic Stress Disorder. Journal of Nepal Medical Association, [S.l.], v. 55, n. 206, june 2017. ISSN 1815-672X. Available at: <http://jnma.com.np/jnma/index.php/jnma/article/view/3108>. Date accessed: 20 aug. 2017.
Review Article